posaconazole
posaconazole is listed in the FDA National Drug Code directory with 22 NDC codes, marketed under brand names including NOXAFIL, POSACONAZOLE, posaconazole. Available dosage forms: powder, for suspension, suspension, tablet, delayed release, tablet, coated, solution.
Drug details
- Generic Name
- posaconazole
- Brand Names
- NOXAFIL, POSACONAZOLE, posaconazole
- Application Number
- NDA214770
- Sponsor
- Merck Sharp & Dohme LLC
- NDC Codes
- 22
- Dosage Forms
- POWDER, FOR SUSPENSION, SUSPENSION, TABLET, DELAYED RELEASE, TABLET, COATED, SOLUTION, GRANULE, INJECTION, SOLUTION
- Routes
- ORAL, INTRAVENOUS
- Active Ingredients
- POSACONAZOLE
Indications and Usage
1 INDICATIONS AND USAGE Posaconazole is an azole antifungal indicated as follows: Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) Posaconazole delayed-release tablets: adults and pediatric patients 2 years of age and older who weigh greater than 40 kg 1.2 Prophylaxis of Invasive Aspergillus and Candida Infections Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: Posaconazole delayed-release tablets: adults and pediatric patients 2 years of age and older who weigh greater than 40 kg Additional pediatric use information is approved for Merck Sharp & Dohme LLC NOXAFIL ® (posaconazole) delayed-release tablets. However, due to Merck Sharp & Dohme LLC’s marketing exclusivity rights, this drug product is not labeled with that information.